CIMETIDINE

Post-LOE

cimetidine

Teva

ANDAORALTABLET1 Generic Approved

Approved

May 1994

Lifecycle

Post-LOE

Competitive Pressure

45/100

Clinical Trials

Data completeness

5/8 — Partial

CIMETIDINE (cimetidine) by Teva is histamine h2 receptor antagonists [moa]. Approved for histamine-2 receptor antagonist [epc]. First approved in 1994.

Drug data last refreshed 6h ago

$0.0BPart D

Mechanism of Action

Histamine H2 Receptor Antagonists

Pharmacologic Class:

Histamine-2 Receptor Antagonist

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (6)

NCT03618316Phase 1Completed

Effect of Cimetidine on the PK of Imeglimin

Started Jun 2018

16 enrolled

Healthy

NCT03380455Phase 1Completed

Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

Started Jan 2018

14 enrolled

Healthy Subjects

NCT02287272Phase 1Completed

Drug-drug Interaction Study of CHF5993 With Cimetidine

Started May 2014

25 enrolled

COPD

NCT00800280Phase 1Terminated

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Started Jan 2009

12 enrolled

Generalized Anxiety Disorder

NCT01366378Phase 1Completed

Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX

Started Jan 2007

18 enrolled

Healthy Adult Subjects

Worked on CIMETIDINE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.